Subgroup analysis | Landmark | Surveillance | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TP | FP | FN | TN | Sensitivity | Specificity | AUC | TP | FP | FN | TN | Sensitivity | Specificity | AUC | ||
Lung cancer typeb | Lung cancer (stage I–III) | 145 | 47 | 213 | 846 | 0.41 (0.35–0.46) | 0.95 (0.93–0.96) | 0.84 | 178 | 73 | 55 | 467 | 0.76 (0.70–0.82) | 0.86 (0.83–0.89) | 0.88 |
NSCLC (stage I–III) | 140 | 44 | 205 | 836 | 0.41 (0.35–0.46) | 0.95 (0.93–0.96) | 0.86 | 169 | 70 | 53 | 460 | 0.76 (0.70–0.82) | 0.87 (0.84–0.90) | 0.88 | |
SCLCa | 3 | 3 | 8 | 9 | 0.27 (0.06–0.61) | 0.75 (0.43–0.95) |  | 9 | 3 | 2 | 6 | 0.82 (0.48–0.98) | 0.67 (0.30–0.93) |  | |
Stage | Patients at stage I ≥ 50% (NSCLC) | 55 | 25 | 123 | 581 | 0.31 (0.24–0.38) | 0.96 (0.94–0.97) | 0.81 | 62 | 31 | 21 | 262 | 0.75 (0.64–0.84) | 0.89 (0.85–0.93) | 0.87 |
Patients at stage I < 50% (NSCLC) | 85 | 19 | 82 | 255 | 0.51 (0.43–0.59) | 0.93 (0.89–0.96) | 0.90 | 107 | 39 | 32 | 198 | 0.77 (0.69–0.84) | 0.84 (0.78–0.88) | 0.87 | |
Patients at stage I < 50% (lung cancer) | 90 | 22 | 90 | 265 | 0.50 (0.42–0.58) | 0.92 (0.89–0.95) | 0.88 | 116 | 42 | 34 | 207 | 0.77 (0.70–0.84) | 0.83 (0.78–0.87) | 0.87 | |
Definitive therapy | Surgery (NSCLC) | 108 | 40 | 197 | 801 | 0.35 (0.29–0.40) | 0.95 (0.94–0.97) | 0.77 | 153 | 70 | 48 | 449 | 0.76 (0.70–0.82) | 0.87 (0.83–0.89) | 0.87 |
Detection method | Amplicon NGS (NSCLC) | 31 | 7 | 42 | 97 | 0.42 (0.31–0.55) | 0.93 (0.87–0.97) | 0.43 | 44 | 17 | 13 | 75 | 0.77 (0.64–0.87) | 0.82 (0.72–0.89) | 0.90 |
Hybrid Capture NGS (NSCLC) | 104 | 32 | 163 | 727 | 0.39 (0.33–0.45) | 0.96 (0.94–0.97) | 0.88 | 125 | 53 | 40 | 385 | 0.76 (0.68–0.82) | 0.88 (0.84–0.91) | 0.87 | |
Hybrid Capture NGS (lung cancer) | 109 | 35 | 171 | 737 | 0.39 (0.33–0.45) | 0.95 (0.94–0.97) | 0.85 | 134 | 56 | 42 | 392 | 0.76 (0.69–0.82) | 0.88 (0.84–0.90) | 0.86 | |
Detection strategy | Tumor-informed (NSCLC) | 69 | 27 | 146 | 533 | 0.32 (0.26–0.39) | 0.95 (0.93–0.97) | 0.78 | 99 | 46 | 44 | 243 | 0.69 (0.61–0.77) | 0.84 (0.79–0.88) | 0.87 |
Tumor-agnostic (NSCLC) | 42 | 9 | 27 | 92 | 0.61 (0.48–0.72) | 0.91 (0.84–0.96) | 0.97 | 29 | 19 | 3 | 33 | 0.91 (0.75–0.98) | 0.63 (0.49–0.76) | 0.97 | |
Tumor-agnostic (lung cancer) | 47 | 12 | 35 | 102 | 0.57 (0.46–0.68) | 0.89 (0.82–0.94) | 0.98 | 38 | 22 | 5 | 40 | 0.88 (0.75–0.96) | 0.65 (0.51–0.76) | 0.94 |